CCL2 and hepatocellular carcinoma: Moreover, Zhou et al. proposed that highly expressed CCL2 and CCL17 in tumor-associated neutrophils promoted the infiltration of macrophages and regulatory T cells, thus compromising sorafenib efficacy in HCC (Zhou et al., 2016).